Works by Gilgun-Sherki, Yossi

Results: 15

The role of oxidative stress in the pathogenesis of multiple sclerosis: The need for effective antioxidant therapy.

Published in:

Journal of Neurology, 2004, v. 251, n. 3, p. 261, doi. 10.1007/s00415-004-0348-9

By:

Gilgun-Sherki, Yossi;
Melamed, Eldad;
Offen, Daniel

Publication type:

Article

Therapeutic Potential of Neurotrophic Factors in Neurodegenerative Diseases.

Published in:

BioDrugs, 2005, v. 19, n. 2, p. 97, doi. 10.2165/00063030-200519020-00003

By:

Levy, Yossef S.;
Gilgun-Sherki, Yossi;
Melamed, Eldad;
Offen, Daniel

Publication type:

Article

A novel thiol antioxidant that crosses the blood brain barrier protects dopaminergic neurons in experimental models of Parkinson's disease.

Published in:

European Journal of Neuroscience, 2005, v. 21, n. 3, p. 637, doi. 10.1111/j.1460-9568.2005.03889.x

By:

Bahat‐Stroomza, Merav;
Gilgun‐Sherki, Yossi;
Offen, Daniel;
Panet, Hana;
Saada, Ann;
Krool‐Galron, Nili;
Barzilai, Aari;
Atlas, Daphne;
Melamed, Eldad

Publication type:

Article

Safety, pharmacokinetics, and pharmacodynamics of TV-1380, a novel mutated butyrylcholinesterase treatment for cocaine addiction, after single and multiple intramuscular injections in healthy subjects.

Published in:

Journal of Clinical Pharmacology, 2015, v. 55, n. 5, p. 573, doi. 10.1002/jcph.450

By:

Cohen‐Barak, Orit;
Wildeman, Jacqueline;
van de Wetering, Jeroen;
Hettinga, Judith;
Schuilenga‐Hut, Petra;
Gross, Aviva;
Clark, Shane;
Bassan, Merav;
Gilgun‐Sherki, Yossi;
Mendzelevski, Boaz;
Spiegelstein, Ofer

Publication type:

Article

Pathological and clinical aspects of alpha/beta synuclein in Parkinson’s disease and related disorders.

Published in:

Expert Review of Neurotherapeutics, 2016, v. 16, n. 5, p. 505, doi. 10.1586/14737175.2016.1164600

By:

Tolmasov, Michael;
Djaldetti, Ruth;
Lev, Nirit;
Gilgun-Sherki, Yossi

Publication type:

Article

Glatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosis.

Published in:

Expert Review of Neurotherapeutics, 2015, v. 15, n. 6, p. 575, doi. 10.1586/14737175.2015.1040768

By:

Boster, Aaron L;
Ford, Corey C;
Neudorfer, Orit;
Gilgun-Sherki, Yossi

Publication type:

Article

MPOWERED Trial Open-Label Extension: Long-term Efficacy and Safety Data for Oral Octreotide Capsules in Acromegaly.

Published in:

Journal of Clinical Endocrinology & Metabolism, 2023, v. 108, n. 12, p. 3214, doi. 10.1210/clinem/dgad365

By:

Fleseriu, Maria;
Molitch, Mark;
Dreval, Alexander;
Pokramovich, Yulia;
Bondar, Irina;
Poteshkin, Yury;
Macut, Djuro;
Obermayer-Pietsch, Barbara;
Gilgun-Sherki, Yossi;
Haviv, Asi;
Biermasz, Nienke;
Strasburger, Christian J.

Publication type:

Article

Erratum to: A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial.

Published in:

2015

By:

Ziemssen, Tjalf;
Bajenaru, Ovidiu;
Carrá, Adriana;
Klippel, Nina;
Correia de Sá, João;
Edland, Astrid;
Frederiksen, Jette;
Heinzlef, Olivier;
Karageorgiou, Klimentini;
Lander Delgado, Rafael;
Landtblom, Anne-Marie;
Macías Islas, Miguel;
Tubridy, Niall;
Gilgun-Sherki, Yossi

Publication type:

Erratum

A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial.

Published in:

Journal of Neurology, 2014, v. 261, n. 11, p. 2101, doi. 10.1007/s00415-014-7446-0

By:

Ziemssen, Tjalf;
Bajenaru, Ovidiu;
Carrá, Adriana;
Klippel, Nina;
Sá, João;
Edland, Astrid;
Frederiksen, Jette;
Heinzlef, Olivier;
Karageorgiou, Klimentini;
Lander Delgado, Rafael;
Landtblom, Anne-Marie;
Macías Islas, Miguel;
Tubridy, Niall;
Gilgun-Sherki, Yossi

Publication type:

Article

Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate.

Published in:

2015

By:

Ziemssen, Tjalf;
Gilgun-Sherki, Yossi

Publication type:

journal article

Central nervous system effects of the histamine‐3 receptor antagonist CEP‐26401, in comparison with modafinil and donepezil, after a single dose in a cross‐over study in healthy volunteers.

Published in:

British Journal of Clinical Pharmacology, 2019, v. 85, n. 5, p. 970, doi. 10.1111/bcp.13885

By:

Baakman, Anne C.;
Zuiker, Rob;
Gerven, Joop M.A.;
Gross, Nicholas;
Yang, Ronghua;
Fetell, Michael;
Gershon, Ari;
Gilgun‐Sherki, Yossi;
Hellriegel, Edward;
Spiegelstein, Ofer

Publication type:

Article

Analysis of gene expression in MOG-induced experimental autoimmune encephalomyelitis after treatment with a novel brain-penetrating antioxidant.

Published in:

Journal of Molecular Neuroscience, 2005, v. 27, n. 1, p. 125, doi. 10.1385/JMN:27:1:125

By:

Gilgun-Sherki, Yossi;
Barhum, Yael;
Atlas, Daphne;
Melamed, Eldad;
Offen, Daniel

Publication type:

Article

Antioxidant treatment in alzheimer’s disease.

Published in:

Journal of Molecular Neuroscience, 2003, v. 21, n. 1, p. 1, doi. 10.1385/JMN:21:1:1

By:

Gilgun-Sherki, Yossi;
Melamed, Eldad;
Offen, Daniel

Publication type:

Article

Disease and Treatment-Related Burden in Patients With Acromegaly Who Are Biochemically Controlled on Injectable Somatostatin Receptor Ligands.

Published in:

Frontiers in Endocrinology, 2021, v. 11, p. N.PAG, doi. 10.3389/fendo.2021.627711

By:

Fleseriu, Maria;
Molitch, Mark;
Dreval, Alexander;
Biermasz, Nienke R.;
Gordon, Murray B.;
Crosby, Ross D.;
Ludlam, William H.;
Haviv, Asi;
Gilgun-Sherki, Yossi;
Mathias, Susan D.

Publication type:

Article

A low molecular weight copper chelator crosses the blood–brain barrier and attenuates experimental autoimmune encephalomyelitis.

Published in:

Journal of Neurochemistry, 2004, v. 89, n. 5, p. 1241, doi. 10.1111/j.1471-4159.2004.02428.x

By:

Offen, Daniel;
Gilgun-Sherki, Yossi;
Barhum, Yael;
Benhar, Moran;
Grinberg, Leonid;
Reich, Reuven;
Melamed, Eldad;
Atlas, Daphne

Publication type:

Article